CAR T-cell therapy for returning multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with multiple myeloma (a cancer of plasma cells).
- You have already tried at least 3 different treatments for this cancer, and it has come back or not responded.
- Your cancer must be measurable (shows up on tests), and you should be otherwise healthy enough to participate.
- You have not previously had a treatment that targets a protein called GPRC5D on the cancer cells.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study or for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new treatment called VV169, a type of CAR T cell therapy, for people with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if it is safe and if it can help fight the cancer.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.